Immuneering Corporation (IMRX)

1.6400 +0.0800 (+5.13%) At close: 04:00PM EDT

Immuneering Corporation

245 Main Street
Second Floor
Cambridge, MA 02142
United States
617 500 8080
https://immuneering.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 68

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Benjamin J. Zeskind M.B.A., Ph.D.	Co-Founder, President, CEO & Director	935.09k	N/A	1983
Mr. Robert J. Carpenter M.B.A., M.S.	Co-Founder & Chair Emeritus	75.36k	N/A	1946
Dr. Brett M. Hall Ph.D.	Chief Scientific Officer	905.41k	N/A	1969
Mr. Harold E. Brakewood	Chief Business Officer	579.77k	N/A	1966
Ms. Paula George CPA	Director of Accounting & Operations and Assistant Corporate Controller	N/A	N/A	N/A
Mr. Michael D. Bookman J.D.	Chief Legal Officer & Secretary	N/A	N/A	1987
Ms. Leah R. Neufeld	Chief People Officer	N/A	N/A	1973
Dr. Peter King Ph.D.	Head of Discovery & VP	N/A	N/A	N/A
Dr. Praveen Nair Ph.D.	Head of Translational Pharmacology & VP	N/A	N/A	N/A
Mr. Stephen Sebastian CPA	Executive Director & Corporate Controller	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Corporate Governance

Immuneering Corporation’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 7; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.